Quality Discovery & Development programs and innovative Platforms, including; Cancer & Cancer Immunology studies with pharmacodynamic endpoints; Advanced PDX models, Rapid, sensitive CTC Analysis, Target Specific Antibody Detection, Platform delivering macromolecules intracellularly. Collaborative Drug Discovery and Development Programs for biologics and small molecules leveraging SRI’s experience and expertise ...